Professor Chris Buckley focusses on understanding the immunobiology of the stromal microenvironment, a key therapeutic target for both chronic inflammatory conditions and cancer.
Professor of Rheumatology and Clinical Director for Centre of Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham Research Laboratories, Queen Elizabeth Hospital
Background and Research focus
Professor Buckley and his group are interested in examining the contribution of tissue resident stromal cells such as macrophages, endothelial cells and fibroblasts in inflammation and the tumour microenvironment. In chronic inflammation the resolution stage is extended and disordered resulting in the persistent accumulation of the inflammatory infiltrate. Their work has led to the proposal that tissue resident fibroblasts orchestrate and maintain the inflammatory infiltrate. In addition, recent studies in human lung, breast, colon and prostate cancer have unequivocally provided a key role for stromal cells (cancer associated fibroblasts) in tumour initiation and progression. Hence, stromal cells represent a highly attractive and novel set of organ specific targets to treat chronic inflammatory diseases and human malignancies.
Chronic inflammatory diseases; tumour microenvironment; stromal cells; inflammation; fibroblast; rheumatoid arthritis.
Chris has made substantial contributions to scientific administration through his roles with the arthritis research UK (Chair of the Fellowship Committee and Clinical Studies Group on early inflammatory arthritis) as well as EULAR (Scientific Programme organizing committee). He also sits on the College’s Integrated Clinical Academic Training committee and is particularly keen on mentoring and supporting medical doctors early in their academic careers.
Barone F, Nayar S, Buckley CD. The role of non-hematopoietic stromal cells in the persistence of inflammation. Front Immunol. 2013 Jan 14;3:416.
Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol. 2013 Jan;13(1):59-66.
Naylor AJ, Filer A, Buckley CD. The role of stromal cells in the persistence of chronic inflammation. Clin Exp Immunol. 2013 Jan;171(1):30-5.
Sherlock JP, Filer AD, Isaacs JD, Buckley CD. What can rheumatologists learn from translational cancer therapy? Arthritis Res Ther. 2013 May 1;15(3):114.
Hou TZ, Mustafa MZ, Flavell SJ, Barrington F, Jenkinson EJ, Anderson G, Lane PJ, Withers DR, Buckley CD. Splenic stromal cells mediate IL-7 independent adult lymphoid tissue inducer cell survival. Eur J Immunol. 2010 Feb;40(2):359-65.
Juarez M, Filer A, Buckley CD. Fibroblasts as therapeutic targets in rheumatoid arthritis and cancer. Swiss Med Wkly. 2012 Feb 24;142:w13529.
McGettrick HM, Butler LM, Buckley CD, Rainger GE, Nash GB. Tissue stroma as a regulator of leukocyte recruitment in inflammation. J Leukoc Biol. 2012 Mar;91(3):385-400.
Buckley CD. Why does chronic inflammation persist: An unexpected role for fibroblasts. Immunol Lett. 2011 Jul;138(1):12-4.
Hardie DL, Baldwin MJ, Naylor A, Haworth OJ, Hou TZ, Lax S, Curnow SJ, Willcox N, MacFadyen J, Isacke CM, Buckley CD. The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation. Immunology. 2011 Jul;133(3):288-95.
Hidalgo E, Essex SJ, Yeo L, Curnow SJ, Filer A, Cooper MS, Thomas AM, McGettrick HM, Salmon M, Buckley CD, Raza K, Scheel-Toellner D. The response of T cells to interleukin-6 is differentially regulated by the microenvironment of the rheumatoid synovial fluid and tissue. Arthritis Rheum. 2011 Nov;63(11):3284-93.